4-Methoxyestradiol, Urine Creatinine Ratio Unit Converter

4-Methoxyestradiol (4-MeO-E2) is a methylated estrogen metabolite produced when the enzyme COMT (catechol-O-methyltransferase) adds a methyl group to 4-hydroxyestradiol (4-OH-E2). This methylation step is part of Phase II estrogen detoxification and converts a potentially harmful catechol estrogen into a safe, inactive end product.

The metabolic pathway runs: estradiol → 4-OH-estradiol (via CYP1B1, Phase I) → 4-MeO-estradiol (via COMT, Phase II). Because unmethylated 4-OH-E2 can oxidize into reactive quinones that damage DNA, this methylation step is considered protective.

The urine creatinine ratio normalizes 4-MeO-E2 concentration against urinary creatinine to account for differences in hydration, providing a consistent measure of excretion regardless of how dilute or concentrated the urine sample is.

4-MeO-E2 is produced primarily in the liver, where COMT methylates 4-OH-E2 using S-adenosylmethionine (SAMe) as the methyl donor and magnesium as a cofactor. COMT is also active in the kidneys, brain, red blood cells, and hormone-sensitive tissues such as the breast and uterus.